HC Wainwright Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lifted by HC Wainwright from $192.00 to $215.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms also recently issued reports on NBIX. Royal Bank Of Canada dropped their price objective on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a report on Thursday, February 12th. JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Citigroup boosted their price objective on shares of Neurocrine Biosciences from $203.00 to $204.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Truist Financial lowered their price objective on Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Finally, Wedbush boosted their price objective on Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $180.70.

Neurocrine Biosciences Stock Down 1.2%

Shares of NASDAQ NBIX opened at $130.90 on Tuesday. The business’s 50 day moving average is $131.46 and its two-hundred day moving average is $138.91. The company has a market cap of $13.14 billion, a P/E ratio of 28.09, a P/E/G ratio of 0.69 and a beta of 0.35. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. During the same quarter in the previous year, the firm posted $1.69 EPS. The business’s revenue for the quarter was up 28.3% compared to the same quarter last year. Sell-side analysts expect that Neurocrine Biosciences will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the sale, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. AlTi Global Inc. grew its position in Neurocrine Biosciences by 1.0% in the third quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock valued at $959,000 after acquiring an additional 70 shares during the period. Huntington National Bank grew its position in Neurocrine Biosciences by 12.6% in the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after acquiring an additional 76 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in Neurocrine Biosciences by 0.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock valued at $1,560,000 after acquiring an additional 77 shares during the period. Perigon Wealth Management LLC grew its position in Neurocrine Biosciences by 3.1% in the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after acquiring an additional 78 shares during the period. Finally, Motley Fool Asset Management LLC grew its position in Neurocrine Biosciences by 4.8% in the fourth quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after acquiring an additional 78 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition materially expands Neurocrine’s commercial footprint — adds VYKAT XR (first‑and‑only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome) and pushes the company into endocrinology/rare metabolic diseases, creating a multi‑product commercial platform alongside INGREZZA and CRENESSITY. Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
• Positive Sentiment: Analysts reacted by lifting price targets and reiterating buys — multiple firms (Citigroup, Canaccord, HC Wainwright, BofA, Needham, Wedbush) raised targets substantially, signaling upside to consensus estimates and investor confidence in the deal’s revenue potential. Vykat XR Acquisition Unlocks Diversified Growth — TipRanks
• Neutral Sentiment: Market validated Soleno’s value — SLNO shares jumped sharply on the deal, confirming the premium paid by Neurocrine and market willingness to pay for VYKAT XR’s orphan indication. This supports deal rationale but doesn’t guarantee NBIX near‑term earnings upside. Soleno Therapeutics Soars 32% on $2.9B Merger
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT XR ahead of the takeover — Neurocrine says it will prioritize the U.S. launch. That could accelerate U.S. commercialization focus but delays/forgoes near‑term EU revenue. Soleno withdraws EU rare disease drug application — Reuters
• Negative Sentiment: Shares dropped on deal announcement — investors appear concerned about the price tag ($2.9B cash), near‑term dilution to capital flexibility or execution risks integrating a new therapeutic area while Neurocrine’s pipeline faces a near‑term lull. This immediate negative reaction drove today’s decline. This Pharma Stock Is Surging 40% — Barron’s
• Negative Sentiment: Some analysts caution on execution and orphan market risks — at least one firm (BMO) kept a Hold, highlighting integration and long‑term execution questions that could cap near‑term multiple expansion. Balanced View on Neurocrine — TipRanks

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.